Sicart Associates’s Allergan plc AGN Stock Holding History

Sicart Associates’s Portfolio AGN Stock Details AGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q1	–	Sell	-9,944	Closed	-$2.09M	–	107
2016 Q4	$2.09M	Buy	+9,944	New	+$2.06M	1.44%	23

Other funds holding AGN

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Sicart Associates's AGN Position: Q1 2017 in Review

Sicart Associates sold out of Allergan plc (AGN) in Q1 2017, closing a stake of 9,944 shares — an estimated $2.09M sold.

Sicart Associates first reported a position in AGN in Q4 2016 and held it in 1 quarter. The position peaked at $2.09M in Q4 2016. 1,104 funds tracked by Wall St. Rank hold AGN as of Q1 2017.

Sicart Associates reported no remaining Allergan plc position as of Q1 2017 after selling out during the quarter.
Sicart Associates sold 9,944 Allergan plc shares in Q1 2017, an estimated $2.09M.
Sicart Associates first reported a position in Allergan plc in Q4 2016 and held it in 1 quarter.
Sicart Associates's Allergan plc position peaked at $2.09M in Q4 2016.
1,104 funds tracked by Wall St. Rank held Allergan plc as of Q1 2017.

Based on Sicart Associates's 13F filing for Q1 2017, filed 10 Apr 2017.